Despite substantial progress in the development of antiretroviral regimens that durably
suppress Human Immunodeficiency Virus (HIV) infection, new agents that maintain high …

Hepatitis B virus (HBV) is a hepatotropic virus that can establish a persistent and chronic
infection in humans through immune anergy. Currently, 3.5% of the global population is …

Background The novel prodrug tenofovir alafenamide delivers the nucleotide reverse
transcriptase inhibitor tenofovir to target cells more efficiently at a lower dose than tenofovir …

Background & Aims Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to
treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir …

Background Tenofovir alafenamide is a novel prodrug formulated to deliver the active
metabolite to target cells more efficiently than tenofovir disoproxil fumarate at a lower dose …

Background Treatment with tenofovir disoproxil fumarate has been associated with renal
toxicity or reductions in bone mineral density, or both, in some patients with chronic hepatitis …

Current therapies of chronic hepatitis B (CHB) remain limited to pegylated-interferon-alpha
(PegIFN-α) or any of the five approved nucleos (t) ide analogues (NUC) treatments. While …

Background & Aims Chronic hepatitis B (CHB) infection remains the most frequent etiology
of hepatocellular carcinoma globally as well as a major cause of cirrhosis. Despite …

Abstract Background & Aims Tenofovir disoproxil fumarate (TDF) is a first‐line treatment for
chronic hepatitis B (CHB). We aimed to describe the efficacy and safety profiles of TDF …

Tenofovir alafenamide (TAF) can be considered a new prodrug of tenofovir (TFV), as
successor of tenofovir disoproxil fumarate (TDF). It is in vivo as potent against human …